Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Pacira BioSciences, Inc.

Get SEC filing alerts via email and in your feed for Pacira BioSciences, Inc.

PCRX

Pacira BioSciences, Inc.

About Pacira BioSciences, Inc.

Pacira BioSciences specializes in developing and commercializing non-opioid pain management therapies, including long-acting local anesthetics, corticosteroids, and nerve block devices. Its core products—EXPAREL, ZILRETTA, and iovera—serve surgical, orthopedic, and pain relief markets, emphasizing opioid reduction and enhanced recovery. The company leverages proprietary drug delivery and nerve modulation technologies to provide safe, effective, and targeted pain solutions for diverse patient populations.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Pacira BioSciences, Inc.

1
1
Pacira BioSciences, Inc. Pacira BioSciences Reports 5% Revenue Growth to $177.4 Million in Q1 2026

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
Pacira BioSciences, Inc. Pacira BioSciences Reports $726.4 Million Revenue for Fiscal Year 2025, Driven by EXPAREL Sales

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Pacira BioSciences, Inc. Pacira BioSciences Reports $179.5M Revenue in Q3 2025, Net Income Recovery

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Pacira BioSciences, Inc. Pacira BioSciences Reports Q2 2025 Revenue Growth but Net Loss

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Pacira BioSciences, Inc. Pacira BioSciences Reports Q1 2025 Financial Results with $168.9M Revenue

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Pacira BioSciences, Inc. Pacira BioSciences Reports $700.97 Million Revenue with 4% Growth and $99.6 Million Net Loss

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
Pacira BioSciences, Inc. Pacira BioSciences Reports Revenue Growth, Increased Losses in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments